{"id":5650,"date":"2023-12-13T11:11:33","date_gmt":"2023-12-13T16:11:33","guid":{"rendered":"https:\/\/neoaptamers.com\/?p=5650"},"modified":"2026-04-13T13:12:50","modified_gmt":"2026-04-13T17:12:50","slug":"aptamarker-breaking-barriers-animal-trials-to-human-trials","status":"publish","type":"post","link":"https:\/\/neoaptamers.com\/fr\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","title":{"rendered":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials"},"content":{"rendered":"<ul>\n<li><strong>Avantage de la tol\u00e9rance immunitaire des Aptamarkers :<\/strong> Les Aptamarkers surmontent les probl\u00e8mes de tol\u00e9rance immunitaire dans le d\u00e9veloppement traditionnel des anticorps.<\/li>\n<li><strong>Aptamarkers vs. Anticorps : Un Avantage Quantitatif :<\/strong> Un spectre de reconnaissance plus large aligne le paysage des biomarqueurs chez les mod\u00e8les animaux plus \u00e9troitement avec le contexte humain.<\/li>\n<li><strong>Formation des Aptamarkers lors des essais sur les animaux :<\/strong> Les Aptamarkers peuvent \u00eatre form\u00e9s lors des essais sur les animaux, facilitant ainsi les travaux pr\u00e9paratoires pour les essais sur l'homme. En affinant et en optimisant les Aptamarkers chez les animaux, on garantit une transition plus fluide vers les applications humaines, ce qui r\u00e9duit les d\u00e9fis impr\u00e9vus lors des essais cliniques.<\/li>\n<\/ul>\n<p>La traduction des d\u00e9couvertes biom\u00e9dicales des mod\u00e8les animaux aux applications humaines est un pont essentiel dans le parcours du d\u00e9veloppement de m\u00e9dicaments. La plateforme Aptamarker de NeoVentures Biotechnology se pr\u00e9sente comme une force transformatrice dans ce processus, offrant une solution unique aux d\u00e9fis rencontr\u00e9s dans le d\u00e9veloppement traditionnel d'anticorps. Dans ce blog, nous plongeons dans les complexit\u00e9s de la traduction des biomarqueurs des animaux aux humains, en montrant comment les Aptamarkers, avec leurs avantages distincts, r\u00e9volutionnent cet aspect crucial de la recherche biom\u00e9dicale.<\/p>\n<h2>L'avantage de tol\u00e9rance immunitaire des Aptamarkers<\/h2>\n<p>Le d\u00e9veloppement traditionnel des anticorps rencontre souvent des d\u00e9fis li\u00e9s \u00e0 la tol\u00e9rance immunitaire, limitant la d\u00e9tection des \u00e9pitopes orthologues, c'est-\u00e0-dire des structures \u00e9quivalentes entre les esp\u00e8ces. Les Aptamarkers, en raison de leur absence de tol\u00e9rance immunitaire, surmontent cette barri\u00e8re, ce qui leur permet de d\u00e9tecter un \u00e9ventail plus large d'\u00e9pitopes orthologues. Cette caract\u00e9ristique unique signifie que les Aptamarkers peuvent reconna\u00eetre des \u00e9pitopes qui seraient \u00e9limin\u00e9s lors du d\u00e9veloppement des anticorps, ce qui se traduit par une capacit\u00e9 de d\u00e9tection de biomarqueurs plus \u00e9tendue et inclusive.<\/p>\n<h2>Aptamarkers contre Anticorps : Un Avantage Quantitatif<\/h2>\n<p>Le manque de tol\u00e9rance immunitaire dans le d\u00e9veloppement des Aptamarkers se traduit par un avantage quantitatif. En d'autres termes, plus d'Aptamarkers peuvent se lier \u00e0 un biomarqueur donn\u00e9 par rapport aux anticorps. Cette abondance d'opportunit\u00e9s de liaison amplifie le potentiel de traduction entre les essais sur animaux et les essais sur l'homme. Le spectre de reconnaissance plus large garantit que le paysage des biomarqueurs identifi\u00e9 dans les mod\u00e8les animaux s'aligne plus \u00e9troitement sur le contexte humain, fournissant aux chercheurs une base plus pr\u00e9cise et plus traduisible.<\/p>\n<h2>La formation des Aptamarkers lors des essais sur animaux<\/h2>\n<p>La polyvalence des Aptamarkers s'\u00e9tend au-del\u00e0 de leurs capacit\u00e9s am\u00e9lior\u00e9es de d\u00e9tection des biomarqueurs. Les Aptamarkers peuvent \u00eatre form\u00e9s lors d'essais sur animaux, permettant aux chercheurs de pr\u00e9parer le terrain pour les essais sur les humains ult\u00e9rieurs. Cette approche proactive permet un d\u00e9pistage pr\u00e9coce des effets du traitement, am\u00e9liorant ainsi l'efficacit\u00e9 du processus de d\u00e9veloppement de m\u00e9dicaments. La capacit\u00e9 \u00e0 ajuster et \u00e0 optimiser les Aptamarkers dans des mod\u00e8les animaux assure une transition plus fluide vers les applications humaines, r\u00e9duisant ainsi le risque de d\u00e9fis impr\u00e9vus lors des essais cliniques.<\/p>\n<h2>La Plateforme Aptamarker : Une Nouvelle Science<\/h2>\n<p>La plateforme Aptamarker repr\u00e9sente un changement de paradigme dans le domaine du d\u00e9veloppement des biomarqueurs. En tant que nouvelle science, elle ouvre des portes \u00e0 des possibilit\u00e9s et des applications innovantes qui \u00e9taient autrefois entrav\u00e9es par les limitations des m\u00e9thodes traditionnelles. Les caract\u00e9ristiques uniques des Aptamarkers invitent \u00e0 la collaboration et \u00e0 l'exploration, encourageant les chercheurs et les partenaires \u00e0 contribuer leurs r\u00e9flexions et leurs id\u00e9es pour \u00e9largir les horizons de cette technologie transformative.<\/p>\n<h2>Partenariats collaboratifs pour la r\u00e9solution de probl\u00e8mes<\/h2>\n<p>Chez NeoVentures Biotechnologie, nous reconnaissons le potentiel de la plateforme Aptamarker et sommes d\u00e9di\u00e9s aux partenariats collaboratifs. Nous invitons les chercheurs, les scientifiques et les organisations \u00e0 se joindre \u00e0 nous pour explorer les vastes applications de cette technologie. L'engagement \u00e0 travailler collectivement pour appliquer les Aptamarkers \u00e0 la r\u00e9solution de probl\u00e8mes du monde r\u00e9el illustre notre vision d'un avenir o\u00f9 la recherche biom\u00e9dicale est avanc\u00e9e gr\u00e2ce \u00e0 une expertise partag\u00e9e et \u00e0 des solutions innovantes.<\/p>\n<h2>Lib\u00e9rer le potentiel des Aptamarkers<\/h2>\n<p>En conclusion, la traduction des biomarqueurs des animaux vers les humains est une \u00e9tape cruciale dans le d\u00e9veloppement de m\u00e9dicaments, et la plateforme Aptamarker de NeoVentures Biotechnology ouvre la voie \u00e0 une approche r\u00e9volutionnaire. En exploitant l'absence de tol\u00e9rance immunitaire, l'avantage quantitatif par rapport aux anticorps et la capacit\u00e9 \u00e0 \u00eatre form\u00e9s lors d'essais sur des animaux, les Aptamarkers garantissent une transition transparente entre les phases pr\u00e9cliniques et cliniques. Alors que nous nous lan\u00e7ons dans cette nouvelle science, nous accueillons avec enthousiasme la collaboration pour lib\u00e9rer pleinement le potentiel des Aptamarkers et remodeler le paysage de la recherche biom\u00e9dicale. Ensemble, nous pouvons ouvrir la voie \u00e0 un avenir o\u00f9 des solutions innovantes naissent de la convergence de perspectives diverses et de technologies de pointe.<\/p>","protected":false},"excerpt":{"rendered":"<p>Immune Tolerance Advantage of Aptamarkers: Aptamarkers overcome immune tolerance issues in traditional antibody development. Aptamarkers vs. Antibodies: A Quantitative Advantage: Broader recognition spectrum aligns the biomarker landscape in animal models more closely with the human context. Training Aptamarkers in Animal Trials: Aptamarkers can be trained in animal trials, facilitating groundwork for subsequent human trials. Fine-tuning&hellip;&nbsp;<a href=\"https:\/\/neoaptamers.com\/fr\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/\" rel=\"bookmark\">Lire la suite &raquo;<span class=\"screen-reader-text\">Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":5652,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[8,39],"tags":[],"class_list":["post-5650","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aptamers","category-case-studies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials<\/title>\n<meta name=\"description\" content=\"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/fr\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials\" \/>\n<meta property=\"og:description\" content=\"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/fr\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-13T16:11:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T17:12:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Gregory Penner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gregory Penner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\"},\"author\":{\"name\":\"Gregory Penner\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\"},\"headline\":\"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials\",\"datePublished\":\"2023-12-13T16:11:33+00:00\",\"dateModified\":\"2026-04-13T17:12:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\"},\"wordCount\":629,\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Blog-images4.png\",\"articleSection\":[\"Aptamers\",\"Case Studies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\",\"name\":\"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Blog-images4.png\",\"datePublished\":\"2023-12-13T16:11:33+00:00\",\"dateModified\":\"2026-04-13T17:12:50+00:00\",\"description\":\"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Blog-images4.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Blog-images4.png\",\"width\":1000,\"height\":800,\"caption\":\"dropper and Petry dish\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/aptamarker-breaking-barriers-animal-trials-to-human-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/person\\\/641d6a3e016e13414b8d0d0ffd5847ad\",\"name\":\"Gregory Penner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g\",\"caption\":\"Gregory Penner\"},\"description\":\"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials","description":"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/fr\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","og_locale":"fr_FR","og_type":"article","og_title":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials","og_description":"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.","og_url":"https:\/\/neoaptamers.com\/fr\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","og_site_name":"neoaptamers","article_published_time":"2023-12-13T16:11:33+00:00","article_modified_time":"2026-04-13T17:12:50+00:00","og_image":[{"width":1000,"height":800,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","type":"image\/png"}],"author":"Gregory Penner","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Gregory Penner","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#article","isPartOf":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/"},"author":{"name":"Gregory Penner","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad"},"headline":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials","datePublished":"2023-12-13T16:11:33+00:00","dateModified":"2026-04-13T17:12:50+00:00","mainEntityOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/"},"wordCount":629,"publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","articleSection":["Aptamers","Case Studies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","url":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/","name":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#primaryimage"},"image":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","datePublished":"2023-12-13T16:11:33+00:00","dateModified":"2026-04-13T17:12:50+00:00","description":"Translating biomarkers from animals to humans, showcasing how Aptamarkers are revolutionizing this crucial aspect of biomedical research.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#primaryimage","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2023\/12\/Blog-images4.png","width":1000,"height":800,"caption":"dropper and Petry dish"},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/aptamarker-breaking-barriers-animal-trials-to-human-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"Aptamarker: Breaking Barriers \u2013 Animal Trials to Human Trials"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]},{"@type":"Person","@id":"https:\/\/neoaptamers.com\/#\/schema\/person\/641d6a3e016e13414b8d0d0ffd5847ad","name":"Gregory Penner","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de665d788f86991000373f8dc389e0f6dcbb9228ffc3b4920b098d16c7c491e8?s=96&d=mm&r=g","caption":"Gregory Penner"},"description":"Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. \u00a0He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases. Connect with Dr. Penner on LinkedIn or for company updates, follow NeoVentures. Click here to get in touch with our team."}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/comments?post=5650"}],"version-history":[{"count":3,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5650\/revisions"}],"predecessor-version":[{"id":6499,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/posts\/5650\/revisions\/6499"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media\/5652"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media?parent=5650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/categories?post=5650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/tags?post=5650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}